Use of integrin a5b1 as target in screening of drugs for preventing and/or treating bone loss

Abstract

The present application relates to the technical field of medicine. Provided is the use of integrin α5β1 as a target in the screening of drugs for preventing and/or treating bone loss. 8-isoprenyl flavone glycoside can replace a ligand fibronectin on cell surface receptor integrin α5β1, thereby achieving the binding of 8-isoprenyl flavone glycoside to the integrin α5β1, and thus improving the osteogenesis ability and the cell adhesion. Therefore, by using integrin α5β1 as a target of a drug for preventing and/or treating bone loss, and by means of the binding of 8-isoprenyl flavone glycoside to integrin α5β1, the activities of ALP, RhoA and Rac1 in bone marrow stromal cells can be significantly improved, thereby promoting the osteogenesis and the cell adhesion, promoting the development of drugs for bone loss, and providing a new strategy and routine for the treatment of bone loss diseases.

Dependencies are inferred from the claim text.